ProKidney
PROK
About: ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Employees: 204
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
9.85% less ownership
Funds ownership: 37.05% [Q1] → 27.2% (-9.85%) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
19% less funds holding
Funds holding: 69 [Q1] → 56 (-13) [Q2]
39% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 33
50% less capital invested
Capital invested by funds: $42M [Q1] → $20.9M (-$21.2M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
UBS
Eliana Merle
|
$8
|
Buy
Maintained
|
15 Jul 2025 |
|
Guggenheim
Vamil Divan
|
$7
|
Buy
Maintained
|
14 Jul 2025 |
|
Citigroup
Yigal Nochomovitz
|
$9
|
Buy
Maintained
|
9 Jul 2025 |
|
B of A Securities
Jason Gerberry
|
$1
|
Underperform
Downgraded
|
30 Jun 2025 |
Financial journalist opinion
Based on 3 articles about PROK published over the past 30 days
